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Introduction
Parkinson’s disease (PD) is characterized by the selective loss of dopaminergic neurons of the
substantia nigra pars compacta (SNpc). Proteostasis impairment at the level of the endoplasmic
reticulum (ER) is emerging as a driving factor of dopaminergic neuron loss in PD. ER stress engages
the activation of an adaptive reaction known as the unfolded protein response (UPR) to recover
proteostasis or trigger apoptosis of damaged cells. The therapeutic potential of the UPR as a target
has been recently validated using pharmacological and gene therapy approaches. A complex view
is emerging where ER stress may have a dual role in PD, both in maintaining cell survival during
initial stages of the diseases and trigger neuronal degeneration when the stress levels are sustained.
Here we overview recent advances in determining the impact of ER stress to PD.
PD is a progressive neurodegenerative disease that affects movement control, characterized by
the loss of dopaminergic neurons in the SNpc. In most PD cases the presence of intracellular inclu-
sions, termed Lewy bodies (LBs) is observed, where fibrillar aggregates of αSynuclein constitute
a major component. Many cellular processes are altered in PD, including redox control, mito-
chondrial function, autophagy/lysosomal function, protein quality control mechanisms, and vesicle
trafficking, among other processes. Accumulating evidence supports disruption in the secretory
pathway as a triggering factor of proteostasis dysfunction in PD, mediating in part the selective
degeneration of dopaminergic neurons (Chua and Tang, 2013; Mercado et al., 2013). Importantly,
in addition to PD, ER stress is emerging as a relevant driver of most common neurodegenerative
diseases (Hetz and Mollereau, 2014).
ER stress activates the UPR, a complex signaling transduction pathway that mediates cellular
adaptation to restore ER function (reviewed in Ron and Walter, 2007; Hetz, 2012). In this article
we discuss recent insights on the significance of ER stress as a driver of dopaminergic neuron loss
in PD and the potential of targeting UPR components to augment the homeostatic capacity of the
ER and reduce pro-apoptotic signals.
ER Stress Signaling
The UPR is a signaling network mediated by the activation of three stress sensors located at
the ER membrane, including inositol requiring kinase 1α (IRE1α), activating transcription factor
6 (ATF6), and protein kinase RNA-like ER kinase (PERK) (Figure 1A). These UPR transduc-
ers control the expression of a variety of genes involved in almost every aspect of the secretory
pathway, resulting in a reduction in the load of misfolded proteins at the ER. Activation of the
UPR improves the efficiency of protein folding and quality control mechanisms, in addition to
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enhance ER andGolgi biogenesis, protein secretion and the clear-
ance of abnormally folded proteins through the autophagy and
ER-associated degradation (ERAD) pathways. However, under
chronic ER stress UPR sensors shifts their signaling toward
induction of cell death by apoptosis (Urra et al., 2013).
IRE1α is an endoribonuclease that processes the mRNA
encoding the transcription factor X-Box binding protein-1
(XBP1) which results in the expression of amore stable and active
transcription factor, termed XBP1s (Ron and Walter, 2007).
Upon activation, ATF6 traffics to the Golgi and undergoes sub-
sequent proteolytic processing to release ATF6f, an active tran-
scriptional factor (Ron andWalter, 2007). PERK is an ER-located
kinase that upon activation phosphorylates the eukaryotic initi-
ation factor 2α (eIF2α), attenuating general protein translation.
In turn, eIF2α phosphorylation leads to the specific translation
of activating transcription factor 4 (ATF4), which up-regulates
many important genes functioning in redox control, amino acid
metabolism and protein folding (Harding et al., 2003). Under
chronic stress, ATF4 regulates the expression of pro-apoptotic
genes such as CHOP.
ER Stress in PD
Themechanisms leading to ER stress in PD and the actual impact
of the UPR on the degeneration cascade are just starting to be
uncovered. A genetic screening in yeast revealed that one of the
major physical targets of αSynuclein is Rab1, an essential com-
ponent of the ER-to-Golgi trafficking machinery (Cooper et al.,
2006; Gitler et al., 2008). Over-expression of Rab1 in animalmod-
els of PD reduced stress levels and protected dopaminergic neu-
rons against degeneration (Coune et al., 2011). Importantly, the
generation of neuronal cultures from induced pluripotent stem
cells (iPSC)-derived from PD patients revealed major proteosta-
sis alterations (Chung et al., 2013). The authors provided evi-
dence indicating that ER stress is a salient molecular signature of
human PD neurons. There are many other studies linking other
PD genes with alteration of the secretory pathway, including
LRRK2, Parkin, Pael-R, DJ-1, ATP13A2 (reviewed in Mercado
et al., 2013), and VPS35 (Zimprich et al., 2011). These reports
suggest that secretory pathway dysfunction is a common hall-
mark of PD, which may result in pathological levels of ER stress
contributing to the etiology of the disease.
The UPR and Cell Fate in PD
Genetic manipulation of essential UPR components in the con-
text of PD had been performed only in a few studies (Figure 1B).
For example, ATF6α knockout animals showed increased accu-
mulation of ubiquitin-positive inclusions and enhanced loss of
dopaminergic neurons induced by a PD-triggering neurotoxin
(Egawa et al., 2011). Although ATF6 is not essential for develop-
ment and survival of dopaminergic neurons in mice, this stress
sensor controls the levels of the chaperone BiP and ERAD com-
ponents under resting conditions in these neurons (Egawa et al.,
2011). A recent study determined that ATF6 is a direct target of
αSynuclein. Expression of αSynuclein was shown to inhibit the
processing of ATF6 through a physical association, leading to an
impaired up-regulation of ERAD genes, which sensitized cells to
apoptosis (Credle et al., 2015).
We recently reported a set of in vivo studies uncovering
the significance of the UPR transcription factor XBP1 in con-
trolling the survival of dopaminergic neurons (Valdes et al.,
2014). We found that the developmental ablation of Xbp1
in the nervous system preconditioned dopaminergic neurons
and rendered them resistant to the PD-triggering neurotoxin
6-hydroxydopamine (6-OHDA) (Figure 1B). This neuroprotec-
tive effect was accompanied by the up-regulation of several UPR
effectors in the SNpc of animals in the absence of pro-apoptotic
markers such as Chop. This phenotype correlated with the pres-
ence of poly-ubiquitinated proteins and large inclusion bodies
in dopaminergic neurons of XBP1 deficient animals, resembling
the classical alterations observed in PD. Remarkably, dopamin-
ergic neurons were prompt to undergo proteostasis alterations
in the absence of XBP1, a phenomenon not observed in other
brain areas including cortex, striatum, or spinal cord (Hetz et al.,
2009; Valenzuela et al., 2012; Vidal et al., 2012; Valdes et al., 2014).
We proposed that developmental targeting of XBP1 provides
neuroprotection through an “ER-hormesis” mechanism where
the occurrence of mild non-lethal ER stress engages an adaptive
response that sustains neuronal function in the absence of XBP1,
which also renders dopaminergic neurons more resistance to a
PD-inducing stimulus. In agreement with this concept, establish-
ment of an ER-hormesis condition (Matus et al., 2012) by the
administration of low doses of the ER stress agent tunicamicyn
on a rodent and flymodel of PD selectively engaged adaptive UPR
signaling events involving the expression of XBP1s (Fouillet et al.,
2012).
Since genetic manipulations during development can lead to
compensatory mechanisms that mask the direct biological effects
of a certain gene, we then targeted XBP1 in adult animals locally
at the SNpc (Valdes et al., 2014). Knocking down XBP1 resulted
in chronic ER stress involving the up-regulation of Chop, caus-
ing spontaneous neurodegeneration of dopaminergic neurons
(Figure 1C). These results highlight the importance of XBP1 in
sustaining dopaminergic neuron function and viability, reinforc-
ing the concept that ER stress is a factor underling their differ-
ential neuronal vulnerability. Therapeutic strategy to artificially
engage a UPR adaptive program has been developed to pre-adapt
dopaminergic neurons to a PD-inducing event. Using a gene
therapy approach, we delivered active XBP1s into the SNpc of
adult mice using adeno-asociated viral (AAVs) vectors (Valdes
et al., 2014). This strategy conferred a dramatic protection against
6-OHDA (Figure 1C), in addition to reduce striatal denervation.
Similarly, a previous report also indicated that XBP1s gene trans-
fer also protects dopaminergic neurons against the PD-inducing
neurotoxin MPTP (Sado et al., 2009).
XBP1 has a conserved role in sustaining dopaminergic neu-
ron survival. Recently, the over-expression of XBP1 was shown to
protect against αSynuclein-induced dopaminergic neuron degen-
eration in C. elegans, whereas neuron-specific RNAi knockdown
of xbp1 exacerbates the neurodegeneration process (Ray et al.,
2014). The unconventional splicing of XBP1 mRNA, in addition
to require the endoribonuclease IRE1α, it involves the RNA lig-
ase RTCB-1. This ligase also confers protection to dopaminergic
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FIGURE 1 | Involvement of ER stress in PD. (A) Schematic
representation of the three branches of the UPR. (B) Knockout (KO) animals
for XBP1, CHOP or ATF6 have been tested to manipulate the UPR in PD
models. (C) Images modified from Valdes et al. (2014): Wild-type mice were
injected into the with (i) AAV expressing an shRNA against XBP1
(shXBP1/GFP), (ii) EGFP alone, or (iii) a vector to overexpress XBP1s. One
month after injection, experimental PD was induced using the 6-OHDA
model to monitor dopaminergic neuron loss at the SNpc. Green: AAV
transduced cells expressing GFP. Red: dopaminergic neurons stained with
anti-tyrosine hydroxylase (TH). Scale bar: 200µm.
neurons against αSynuclein overexpression in C. elegans, uncov-
ering for the first time a functional relationship between XBP1
and its ligase in the regulation of proteostasis in neurons (Ray
et al., 2014). XBP1 expression has been shown to be neuro-
protective also when it is delivered into neural stem cells that
are then transfer into the brain. This strategy, increased the
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survival of the graft and improved the motor performance
in a rotenone-induced rat model of PD (Lihui et al., 2012).
Finally, an AAV-based gene therapy strategy to enhance the
folding capacity of the ER was also evaluated on a genetic
model of PD (Gorbatyuk et al., 2012). Thus, increasing evi-
dence indicates that the local modulation of the UPR in the
nigrostriatal circuit may have important therapeutic potential
in PD.
The UPR is a double-edged sword, cytoprotective when acti-
vated to a moderate extent, but degenerative when it is sustained
over time. Markers of PERK/eIF2α activation have been found
in PD post-mortem brain tissue, where nigral dopaminergic neu-
rons displaying αSynuclein inclusion are also positive for phos-
phorylated PERK and eIF2α (Hoozemans et al., 2007). Deletion
of the pro-apoptotic factor CHOP protects dopaminergic neu-
rons against 6-OHDA and MPTP (Silva et al., 2005) (Figure 1B).
Several strategies are now available to modulate PERK signal-
ing in different disease contexts, including inhibitors of PERK
activity, eIF2α phosphatases, and ATF4 expression (reviewed in
Hetz et al., 2013). Salubrinal, a small compound that enhances
eIF2α (Boyce et al., 2005), was shown to delay disease onset and
attenuate motor deficits induced by αSynuclein over-expression
(Colla et al., 2012). Unexpectedly, although salubrinal treatment
attenuated disease symptoms, its administration did not protect
dopaminergic neurons from degeneration (Colla et al., 2012). In
the last 2 years, new exciting findings implicate the PERK/ATF4
signaling branch of the UPR as an interesting target to treat neu-
rodegenerative diseases (Halliday et al., 2014). In this scenario,
additional tools are available to systematically test the conse-
quences of inhibiting the PERK pathway in PDmodels at the level
of PERK, eIF2α, or ATF4, respectively.
Perspective
Many important questions remain to be solved in this growing
field. Since distinct UPR signaling branches could have specific
and even opposite consequences on neuronal survival depend-
ing on the disease input (Hetz and Mollereau, 2014), a systematic
approach is needed to determine what are the optimal compo-
nents of the UPR pathway as possible targets to develop future
therapeutic interventions. Gene therapy strategies are currently
been developed in PD patients and the first results of phase I
and II clinical trials are available showing excellent safety pro-
files (Coune et al., 2012). In this context, the possible therapeutic
potential and side effects of delivering active UPR components
into the SNpc in the long term remains to be determined in non-
human primates since most of the available studies only used
rapid-evolving PD rodent models. Another interesting aspect to
explore in the future is the cell-non-autonomous control of the
UPR in PD, which may propagate protective responses to other
brain areas and tissues (Mardones et al., 2015). Overall all these
novel insights have placed ER proteostasis in the center of the
etiology of PD, which may translate in the near future into the
development of prototypic strategies to alleviate dopaminergic
neuron loss.
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